Catherine Jacob-Dolan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/785298/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	COVID-19 Vaccines: Adenoviral Vectors. Annual Review of Medicine, 2022, 73, 41-54.	12.2	46
2	Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals. Journal of Infectious Diseases, 2022, 225, 1124-1128.	4.0	15
3	Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters. Npj Vaccines, 2022, 7, 2.	6.0	2
4	Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature, 2022, 603, 493-496.	27.8	326
5	Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice. Npj Vaccines, 2022, 7, 23.	6.0	6
6	Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant. Science Translational Medicine, 2022, 14, eabn6150.	12.4	57
7	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. Cell, 2022, 185, 1549-1555.e11.	28.9	59
8	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2–specific immune responses in rhesus macaques. Science Translational Medicine, 2022, 14, eabm4996.	12.4	13
9	A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaques. Science Translational Medicine, 2022, 14, .	12.4	3
10	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1535.	7.4	260
11	Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. Journal of Virology, 2021, 95, .	3.4	80
12	Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and Infection. Journal of Virology, 2021, 95, .	3.4	24
13	Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. Nature, 2021, 596, 423-427.	27.8	40
14	Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature, 2021, 596, 268-272.	27.8	290
15	Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera. Journal of Virology, 2021, 95, e0040421.	3.4	34
16	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA - Journal of the American Medical Association, 2021, 325, 2370.	7.4	307
17	Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern. Science Translational Medicine, 2021, 13, eabj3789.	12.4	32
18	Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. Science Translational Medicine, 2021, 13, eabj2641.	12.4	15

CATHERINE JACOB-DOLAN

#	Article	IF	CITATIONS
19	Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature, 2021, 590, 630-634.	27.8	995
20	Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines. New England Journal of Medicine, 2021, 385, 2010-2012.	27.0	228
21	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature, 2020, 586, 583-588.	27.8	765
22	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nature Medicine, 2020, 26, 1694-1700.	30.7	275
23	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science, 2020, 369, 812-817.	12.6	789
24	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science, 2020, 369, 806-811.	12.6	978
25	Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβRâ^'/â^' Mice. Cell Host and Microbe, 2019, 26, 591-600.e4.	11.0	26